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Background: In this case–control study we investigated the relative contribution of commons APOA5 polymorphisms
and haplotypes to the risk of metabolic syndrome in Moroccan patients.
Methods: Using the International Diabetes Federation (IDF) criteria for metabolic syndrome, the study included 176
patients and 105 controls. We genotyped APOA5 polymorphisms (−1131 T > C, c.56C > G, c.553G > T and c.1259 T > C)
by PCR-RFLP analysis. The effects of APOA5 polymorphisms and constructed haplotypes on metabolic syndrome were
estimated using logistic regression analyses.
Results: The statistical analysis showed a significant association between APOA5 -1131 T > C and APOA5 c.56C > G
polymorphisms with metabolic syndrome in both Codominant and Dominant models. The APOA5 -1131 T > C
polymorphism was associated with increased fasting glucose (p = 0.0295) and reduced HDL levels (p = 0.0091).
Carriers of the APOA5 c.56G allele had increased triglyceride levels (p = 0.0435) and waist circumference (p = 0.0122).
Similarly the APOA5 1259 T > C variant was associated with increased waist circumference (p = 0.0463). The haplotypes
CCGT (OR = 3.223; p = 0.00278) and CGGT (OR = 8.234; p = 0.00534) were significantly associated with susceptibility to
metabolic syndrome.
Conclusions: Our results confirms the association of APOA5 -1131 T > C and c.56C > G variants with the predisposition
to metabolic syndrome complications.
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The metabolic syndrome (MS) is characterized by the
clustering of several factors: central obesity, raised blood
pressure, raised fasting glucose, elevated triglycerides
(TG) and reduced high-density lipoprotein (HDL) chol-
esterol [1]. Hypertriglyceridemia is the essential lipid
abnormality in MS, and is a direct consequence of the
visceral accumulation of fat, for which the waist circum-
ference is the best surrogate marker [2].
In urban Moroccan women, the prevalence of MS was
about 17.8% [3]. It is a multifactorial disease, besides en-
vironmental factors such as cigarette smoking, obesity,
lack of exercise and bad nutrition habits, genetic factors
also contribute to its pathogenicity [4,5]. Apolipoprotein* Correspondence: hamid.barakat@pasteur.ma
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unless otherwise stated.A5 gene (APOA5) was identified 30 kb upstream of the
well-characterized APOA1/C3/A4 gene cluster on chromo-
some 11. Several studies suggested a strong correlation be-
tween APOA5 and plasma triglycerides levels [6]. Human
APOA5 gene consists of four exons and encodes a 366-
amino acid protein, which is produced only by the liver
and associated with high (HDL) and very low (VLDL)
density lipoproteins particles [7]. Numerous studies have
confirmed the associated between APOA5 alleles such as
1131C, IVS3 + 476A, 1259C, 56G and elevated triglyceride
levels [8,9]. In addition, some APOA5 polymorphisms
confer increased risk for the development of coronary
heart disease and ischemic stroke [10,11].
Two APOA5 common polymorphisms; the −1131 T > C
(SNP3) in the promoter region, and the c.56C >G in the
exon 3 were significantly associated with TG levels in
several population [12-16]. The APOA5 gene variant,
c.553G > T (substitution of a cysteine for a glycine residueral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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higher TG levels in Asian populations [17-19]. In con-
trast, this variant was rare or absent in Caucasian popu-
lations [13,20].
The goal of the present study was to assess the relative
contribution of SNPs in the APOA5 gene to the risk of
metabolic syndrome and we studied the major APOA5
haplogroup profiles in MS patients in Moroccan Patients.
Methods
Study subjects
We dispose 283 subjects recruited from Pasteur Institute
of Morocco in Casablanca, aged between 20 and 60 years,
are from various geographic regions of the country and
are from different ethnic origin (Arab, Amazigh and
Sahraouis). Metabolic syndrome was diagnosed accord-
ing to the criteria of International Diabetes Federation
(IDF) [21]. All patients must have central obesity (waist
circumference ≥ 94 cm for males or ≥ 80 cm for females)
plus at least two of the following criteria: (1) raised
triglycerides level: ≥1.7 mmol/l (150 mg/dL) (or spe-
cific treatment for this lipid abnormality); (2) reduced
HDL-cholesterol: < 1.03 mmol/L (40 mg/dL) in males
and < 1.29 mmol/l (50 mg/dl) in females (or specific treat-
ment for these lipid abnormality); (3) raised blood pres-
sure (BP): systolic BP ≥130 or diastolic BP ≥85 mmHg
(or treatment of previously diagnosed hypertension); (4)
raised fasting plasma glucose (FPG): FPG ≥5.6 mmol/l
(100 mg/dl) (or previously diagnosed type 2 diabetes).
Subjects who met the IDF definition for metabolic syn-
drome were defined as patients, and the remaining indi-
viduals were assigned to the control group. The exclusion
criterion of patients and controls was the presence of any
disease known to influence serum lipid levels, such as thy-
roid disease, renal failure or liver disease. All participants
signed informed consent forms, and the study protocol
was approved by local Committee on Research Ethics of
Pasteur Institut of Morroco.
Clinical and biochemical measurements
Clinical and biochemical parameters were measured by
standard laboratory procedures. Weight and height were
measured to determine body mass index (BMI). BMI
was calculated from height and weight of the individual
by the following formula: Weight (kg)/height (m)2 [22].
Height is usually measured to the nearest 0.5 cm with
stadiometer, without shoes. The weight is measured to
the nearest 0.1 kg on a medical balance scale, the indi-
vidual is lightly dressed and without shoes Waist and
hip circumference were also measured. The systolic and
diastolic blood pressure was measured using a sphygmo-
manometer after 5 minutes minimum of rest in a sitting
position. Both strains were expressed in mmHg (milli-
meters of mercury). At the end of each questionnaire, ablood sample was collected in 2 tubes (for biochemical
analysis and for DNA extraction). Fasting glucose, trigly-
ceride (TG), total cholesterol (Total-C), LDL cholesterol
(LDL-C) and HDL cholesterol (HDL-C) were measured
after 8 hours of fasting. All assays were performed using
an automatic (VITROS).
Molecular analysis
Genomic DNA was extracted from peripheral blood leu-
kocytes by standard phenol-chloroform method. To de-
tect the -1131 T > C (rs662799), c.56C > G (rs3135506),
c.553G > T (rs2075291) and c.1259 T > C (rs2266788)
polymorphisms, polymerase chain reaction (PCR) condi-
tions and restriction fragment length polymorphism
(RFLP) analyses were performed according to previous
published protocols [23-26] (Table 1).
Statistical analysis
Quantitative data were expressed as means ± standard
deviation (SD). Differences between subject groups, ge-
notypes and haplotypes for continuous variables were
assessed by Student test. Manne-Whitney test was used
for variables not normally distributed. Chi-square test
was applied to examine differences in genotype distribu-
tions between cases and controls. Odds ratios (OR) with
95% of confidence intervals (CI) were calculated to as-
sess strength of association. All ORs were adjusted for
sexe, age and body mass index (BMI). Statistical analyses
were performed using STATA software, version 11.0.
The PLINK software v1.07 was used for haplotype fre-
quencies estimation and comparison.
Results
Clinical and biochemical characteristics of MS patients and
control subjects are shown in Table 2. Serum triglycerides,
total cholesterol, LDL-Cholesterol, HDL-Cholesterol and
fasting plasma glucose levels, BMI, Systolic and diastolic
blood pressure values were significantly elevated in the MS
group compared to the controls.
The results of all analyses of association with disease sta-
tus are shown in Table 3. The statistical analysis showed
that the APOA5 -1131 T > C polymorphism was signifi-
cantly associated with MS in both Codominant (OR =
10.13; 95% CI:4.65-22.06; p-value < 0.0001) and Dominant
(OR = 7.82; 95% CI:3.79-16.14; p-value < 0.0001) models.
For the APOA5 c.56C >G polymorphism the statistical
analysis showed a significant association in the codomi-
nant and dominant models with p-value = 0.035 and 0.032
respectively. On the other hand the data analysis of
c.553G > T and c.1259 T > C APOA5 gene polymorphisms
showed a no signification association between this SNPs
and MS in all genetic models.
Additionally, we grouped the carriers for the rare allele
for all SNPs and compared their frequency against the
Table 1 primers and restriction enzymes used for identification of APOA5 polymorphisms
APOA5 SNP forward (F) and reverse (R) primers restriction enzymes PCR-RFLP products Reference
c.1259 T > C (rs 2266788) F: 5’- TCA GTC CTT GAA AGT GGC CT-3’
R: 5’- ATG TAG TGG CAC AGG CTT CC -3’
PCR-product: 287 pb
BseGI TT : 122 and 165 bp [26]
CC : 35, 87and 165 bp
−1131 T > C (rs662799) F: 5’-CCC CAG GAA CTG GAG CGA AATT-3’
R: 5’-TTC AAG CAG AGG GAA GCC TGT A -3’
PCR-product:396 bp
TruI TT : 20, 105, 271 bp [24]
CC : 105 and 291 bp
c.56C > G (rs3135506) F: 5’- GGC TCT TCT TTC AGG TGG GTCTCCG -3’
R:5’- GCC TTT CCG TGC CTG GGT GGT-3’
PCR-product: 157 pb
Taq I CC : 134 and 23 bp [23]
GG : 157 bp
c.553G > T (rs 2075291) F:5’-AGA CAC CAA GGC CCA GTT GCT GGG-3’
R: 5’- ATG CCG CTC ACC AGG CTC TCG GCG -3’
PCR-product: 138 pb
HaeIII TT: 127 and 11 bp [25]
GG : 76, 51 and 11 bp
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riers of the APOA5 -1131C variant were associated with
increased fasting glucose (p = 0.0295) and reduced HDL
levels (p = 0.0091), compared with noncarriers in MS pa-
tients and controls. For the carriers of the APOA5 c.56G
variant were associated with increased triglyceride levels
(p = 0.0435) and Waist circumference (p = 0.0122), com-
pared with noncarriers in MS patients and controls.
Similarly for the APOA5 1259 T > C variant were associ-
ated with increased Waist circumference (p = 0.0463).
The PLINK program was then used to estimate haplo-
type frequencies and identify haplotype association with
disease (Table 5). The study data show that haplotype-
based analysis appears to confirm the SNP analysis with
respect to the association of -1131C and 56G alleles with
MS. Two haplotypes showed significant association with
MS. Haplotypes CCGT (OR = 3.223; 95% CI:1.43-7.25;
p = 0.00278) and CGGT (OR = 8.234; 95% CI:1.6-42.5;
p = 0.00534) confer susceptibility to MS,
The data for the haplotype association are shown in
Table 6. We found only nominal association with BMITable 2 Major clinical parameters of the patients with







Systolic blood pressure 11.43 ± 1.31 13.00 ± 1.76 <0.0001
Diastolic blood pressure 8.34 ± 6.34 8.43 ± 1.24 <0.0001
Total cholesterol 1.90 ± 0.38 2.01 ± 0.46 0.0356
Triglycerides 0.96 ± 0.33 1.54 ± 0.69 <0.0001
LDL-cholesterol 1.16 ± 0.34 1.28 ± 0.37 0.0063
HDL-cholesterol 0.55 ± 0.12 0.48 ± 0.16 0.0001
Fasting plasma glucose 0.85 ± 0.09 1.31 ± 0.54 <0.0001
BMI 25.34 ± 2.93 31.91 ± 14.09 <0.0001
Waist circumference 84.38 ± 10.35 100.47 ± 11.06 <0.0001
HDL: high-density lipoprotein, LDL: low-density lipoprotein, BMI: body
mass index.(p = 0.0269) and waist circumference (p = 0.0268) for
haplotype CGGT.
Discussion
During the last years, the rapid increase in MS preva-
lence in industrialized countries coupled with its devas-
tating complications on human health, mainly because
of a higher risk for developing cardiovascular disease, a
leading cause of death [4]. MS attracted a substantial
interest in deciphering the major genetic factors that
contribute to its pathogenic mechanism [27].
The role of APOA5 polymorphisms (−1131 T > C,
c.56C > G, c.553G > T and c.1259 T > C) and their in-
volvement in various diseases have been studied exten-
sively throughout the world in different populations. To
our knowledge, this is the first study to test the associ-
ation between APOA5 polymorphisms and MS in the
Moroccan population.
We found a strong association between -1131 T > C
polymorphism and MS in both dominant and codomi-
nant models. This association was previously reported
by Maasz et al. in European subjects [25]. A meta-
analysis showed that the -1131 T > C polymorphism was
significantly associated with the MS risk in Asian popu-
lations [28]. Obese adolescents with the -1131C allele
had an increased risk for the development of metabolic
syndrome [29].
The c.56C > G (p.Ser19Trp) polymorphism, resulting
in a substitution of hydrophilic serine to hydrophobic
tryptophan, showed an association with the MS in both
domimant and codominant models. On the other hand,
the statistical analysis of genotype distributions revealed
no association between c.553G > T and c.1259 T > C
APOA5 polymorphisms and MS. In Japanese popula-
tion, the c.553G > T variant significantly associated with
hypertriglyceridemia [30].
Several SNPs in the APOA5 locus have been identified in
humans, four of them, the -1131 T >C, IVS3 + 476G >A,
1259 T >C and c.56C >G represent the most common
Table 3 Association between APOA5 genotypes and Metabolic Syndrome
SNP Model Genotype Controls Patients ORa (95% CI) P-value
−1131 T > C Codominant T/T 65 (61.9%) 48 (28.4%) 1.00
T/C 34 (32.4%) 113 (66.9%) 10.13 (4.65-22.06) <0.0001
C/C 6 (5.7%) 8 (4.7%) 1.49 (0.37-6.00) 0.575
Dominant T/T 65 (61.9%) 48 (28.4%) 1.00
T/C-C/C 40 (38.1%) 121 (71.6%) 7.82 (3.79-16.14) <0.0001
Recessive T/T-T/C 99 (94.3%) 161 (95.3%) 1.00
C/C 6 (5.7%) 8 (4.7%) 0.52 (0.14-1.99) 0.342
c.56C > G Codominant C/C 70 (68%) 93 (53.1%) 1.00
C/G 28 (27.2%) 64 (36.6%) 2.13 (1.05-4.31) 0.035
G/G 5 (4.8%) 18 (10.3%) 1.72 (0.48-6.21) 0.407
Dominant C/C 70 (68%) 93 (53.1%) 1.00
C/G-G/G 33 (32%) 82 (46.9%) 2.07 (1.07-4.03) 0.032
Recessive C/C-C/G 98 (95.2%) 157 (89.7%) 1.00
G/G 5 (4.8%) 18 (10.3%) 1.27 (0.37-4.36) 0.701
c.553G > T Codominant G/G 86 (81.9%) 150 (85.2%) 1.00
G/T 15 (14.3%) 23 (13.1%) 0.97 (0.38-2.48) 0.943
T/T 4 (3.8%) 3 (1.7%) 0.27 (0.05-1.59) 0.148
Dominant G/G 86 (81.9%) 150 (85.2%) 1.00
G/T-T/T 19 (18.1%) 26 (14.8%) 0.73 (0.32-1.71) 0.472
Recessive G/G-G/T 101 (96.2%) 173 (98.3%) 1.00
T/T 4 (3.8%) 3 (1.7%) 0.26 (0.05-1.53) 0.137
c.1259 T > C Codominant T/T 53 (51%) 115 (65.7%) 1.00
T/C 29 (27.9%) 28 (16%) 0.56 (0.25-1.27) 0.166
C/C 22 (21.1%) 32 (18.3%) 0.69 (0.32-1.52) 0.365
Dominant T/T 53 (51%) 115 (65.7%) 1.00
T/C-C/C 51 (49%) 60 (34.3%) 0.63 (0.33-1.17) 0.143
Recessive T/T-T/C 82 (78.8%) 143 (81.7%) 1.00
C/C 22 (21.1%) 32 (18.3%) 0.80 (0.38-1.68) 0.561
a: ORs were adjusted for sexe, age and body mass index (BMI).
Ajjemami et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:29 Page 4 of 8variants. As these genetic natural variants have an effect on
the transcriptional activity of apoa5 protein, some alleles
have been reported to be associated with high plasma TG
levels. The association between -1131C, IVS3 + 476A and
1259C alleles and high TG levels was confirmed in patients
with the metabolic syndrome and in healthy controls [26].
The -1131C allele was significantly associated increased
serum triglyceride levels in Korean subjects [31]. The
modified triglyceride metabolism may be involved in the
abnormal accumulation of fat in the vascular endothelial
cells, and in pathological conditions, it may also be in-
volved in the formation of atheroma plaques which are as-
sociated with disease processes leading to the appearance
ischemic vascular diseases. The -1131 T > C polymorph-
ism have been reported to confer risk of coronary heart
disease and ischemic stroke in many studies in different
populations [10][32].In this study we found that carriers of the APOA5 -1131C
had increased systolic blood pressure, fasting blood glu-
cose and reduced levels of HDL. Similarly, other studies
reported a significant association between low HDL and
this variant in Caucasians [33,34] and Asian populations
[30]. In nonobese Korean men, no significant associ-
ation was found between APOA5 -1131C variant and
fasting plasma glucose [15].
In addition, carriers of the APOA5 c.56G allele had an
increased TG levels and waist circumference compared
to patients and controls non-carriers of this variant. A
similar result was reported in several studies [35,36].
Moreover, the APOA5 c.1259 T > C variant was associ-
ated with higher waist circumference.
Cross-sectional studies have shown that several poly-
morphisms in or near the APOA5-A4-C3-A1 gene, are as-
sociated with triglycerides. In a performed in 199 subjects
Table 4 Comparisons of clinical and biochemical parameters of the study participants according to the APOA5 -1131 T > C, c.56C > G, c.553G > T and c.1259
T > C genotypes
APOA5 -1131 T > C APOA5 c.56C > G APOA5 c.553G > T APOA5 c.1259 T > C
TT TC/CC P CC CG/GG P GG GT/TT P TT TC/CC P
Systolic blood pressure 12.08 ± 1.63 12.60 ± 1.81 0.0162 12.37 ± 1.87 12.50 ± 1.65 0.5348 12.43 ± 1.74 12.37 ± 1.95 0.8487 12.48 ± 1.77 12.34 ± 1.79 0.5173
Diastolic blood pressure 8.75 ± 6.11 8.14 ± 1.21 0.7573 8.18 ± 1.21 8.71 ± 6.06 0.9794 8.47 ± 4.32 7.98 ± 1.16 0.1979 8.59 ± 5.07 8.10 ± 1.16 0.3322
Total cholesterol 1.97 ± 0.39 1.96 ± 0.46 0.8041 1.98 ± 0.45 1.95 ± 0.42 0.5260 1.98 ± 0.42 1.94 ± 0.50 0.5905 1.98 ± 0.43 1.95 ± 0.44 0.6621
Triglycerides 1.23 ± 0.58 1.37 ± 0.68 0.0892 1.24 ± 0.55 1.44 ± 0.75 0.0435 1.31 ± 0.63 1.41 ± 0.70 0.3722 1.34 ± 0.68 1.29 ± 0.59 0.8394
LDL-cholesterol 1.21 ± 0.33 1.26 ± 0.39 0.3161 1.23 ± 0.38 1.24 ± 0.35 0.9080 1.24 ± 0.37 1.23 ± 0.38 0.9020 1.24 ± 0.35 1.22 ± 0.39 0.6142
HDL-cholesterol 0.54 ± 0.15 0.49 ± 0.15 0.0091 0.50 ± 0.14 0.51 ± 0.17 0.5918 0.51 ± 0.15 0.49 ± 0.14 0.5002 0.51 ± 0.16 0.50 ± 0.13 0.4028
Fasting plasma glucose 1.03 ± 0.34 1.20 ± 0.52 0.0295 1.11 ± 0.46 1.18 ± 0.51 0.3953 1.13 ± 0.47 1.17 ± 0.52 0.8328 1.16 ± 0.49 1.11 ± 0.46 0.2787
BMI 30.06 ± 17.46 29.04 ± 5.06 0.2244 29.44 ± 14.81 29.48 ± 5.04 0.0617 29.72 ± 12.59 28.08 ± 5.05 0.4439 29.27 ± 5.35 29.67 ± 17.47 0.0639
Waist circumference 93.53 ± 13.00 94.95 ± 13.77 0.3919 92.75 ± 13.26 96.81 ± 13.18 0.0122 94.68 ± 13.09 93.29 ± 14.47 0.5213 95.73 ± 13.50 92.48 ± 12.92 0.0463


















Table 5 Association analysis of the APOA5 haplotypes
HAPLOTYPE Frequency ORa (95%CI) P-value
Patients Controls
TCGT 0.3941 0.4749 0.6667 (0.406; 1.09 ) 0.106
CCGT 0.2343 0.1485 3.223 (1.43; 7.25 ) 0.00278
TCGC 0.1489 0.2295 0.6331 (0.352; 1.14 ) 0.122
TGGT 0.1196 0.1129 1.013 (0.418; 2.45 ) 0.978
CGGT 0.1032 0.03414 8.234 (1.6; 42.5 ) 0.00534
a: ORs were adjusted for sexe, age and body mass index (BMI).
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morphisms, −1131 T > C and c.56C >G were significantly
associated with Triglycerides and Waist-to-Hip Ratio, re-
spectively [37]. Among patients with clinically manifest
vascular disease, the polymorphism rs964184 in APOA5-
A4-C3-A1 gene cluster was associated with higher plasma
triglycerides concentrations [38].
Our results show no association between APOA5
c.553G > T polymorphism and clinical and biochemical
parameters. In Asian populations, the minor allele of the
APOA5 c.553G > T polymorphism was associated with
higher TG levels [19,39]. This functional variant occurs
in the coding region of APOA5 gene and causes a sub-
stitution of a cysteine by a glycine residue, was suggested
as prognostic indicators for hypertriglyceridemia risk in
Chinese [17]. Another study suggests that the APOA5
c.553G > T polymorphism has no influence directly in
the expression of the APOA5 [39].
In this study, we performed haplotype analysis to
evaluate the susceptibility to MS. We observed that the
CCGT (APOA5*2) haplotype determined by the com-
bination of alleles -1131C, c.56C, c.553G and c.1259 T is
associated with the MS (OR = 3.223, 95% CI:1.43- 7.25,
p = 0.00278), but no association was found with bio-
chemical parameters. However, Kisfali et al. found an as-
sociation between the haplotype APOA5*2 and high
plasma TG levels among patients with MS and controlsTable 6 Association between APOA5 haplotypes with clinical
Haplotype TCGT Haplo
Carriers Noncarriers P-value carrier
Systolic blood pressure 12.47 ± 1.72 12.34 ± 1.86 0.5482 12.46 ±
Diastolic blood pressure 8.62 ± 5.07 8.06 ± 1.14 0.2070 8.04 ±
Total cholesterol 1.98 ± 0.40 1.95 ± 0.49 0.5102 1.96 ±
Triglycerides 1.34 ± 0.67 1.30 ± 0.60 0.9167 1.27 ±
LDL-cholesterol 1.23 ± 0.34 1.25 ± 0.40 0.6883 1.25 ±
HDL-cholesterol 0.51 ± 0.15 0.49 ± 0.15 0.2427 0.48 ±
Fasting plasma glucose 1.17 ± 0.50 1.10 ± 0.46 0.0906 1.18 ±
BMI 29.09 ± 5.20 30.00 ± 17.40 0.4779 28.34 ±
Waist circumference 94.43 ± 11.88 94.50 ± 15.24 0.9685 92.64 ±
HDL: high-density lipoprotein, LDL: low-density lipoprotein, BMI: body mass index.[26], the same result was found in other studies in nor-
mal subjects [13,40].
We found a second association between the CGGT
(APOA5*5) haplotype and increased risk of MS (OR =
8.234, 95%CI: 1.6-42.5, p = 0.0053) and higher BMI (p =
0.0269) and waist circumference (p = 0.0268). Among
the Hungarian population, the APOA5*2 haplotype (the
combination of -1131 T > C, IVS3 + 476G > A and
1259 T > C SNPs) confers risk for the development of
MS (OR = 2.880; 95% CI: 1.567-5.292; p = 0.001), and a
novel haplotype APOA5*5 (1259C allele alone) with a
protective effect against MS was identified [26]. In 2005,
Talmud et al., showed that the polymorphism c.56C > G
which characterize the haplotype APOA5*3, reduced
about 50% secretion of the protein apoAV in a cellular
model of translocation of the protein across the endo-
plasmic reticulum, which could explain the increased
plasma TG in carriers of the APOA5*3 haplotype [41].
Several studies performed association analysis using hap-
lotypes constructed with SNPs located in different genes
including APOA5. A particular haplotype determined by
SNPs in APOA5 and ZNF259 genes, showed significant
association with TG:HDL-C ratio and the risk of MS in
both genders with marked effects in women [42]. Ana-
lysis of constructed haplotypes with SNPs in MTHFR,
APOA5 and APOC3 genes, showed a highly significant
association between one haplotype and MS in the Greek
Population [43]. Gene-gene interaction suggested that
polymorphisms in APOA5 and BTN2A1 genes may have
synergistic effects on the development of MS in Japanese
individuals [44].
There are some limitations in this work, mainly the
low sample size. Replicating our findings in larger Mo-
roccan cohorts from different ethnic groups and geo-
graphic regions, could overcome these limitations and
provide sufficient statistical power to reach clear conclu-
sion on the role of APOA5 polymorphisms in metabolic
syndrome susceptibility. Moreover, only four SNPs inand biochemical parameters
type CCGT Haplotype CGGT
s Noncarriers P-value carriers Noncarriers P-value
1.89 12.40 ± 1.73 0.7790 12.55 ± 1.49 12.39 ± 1.82 0.5936
1.24 8.54 ± 4.66 0.3589 8.07 ± 1.10 8.45 ± 4.30 0.5528
0.48 1.97 ± 0.42 0.7929 2.04 ± 0.44 1.96 ± 0.43 0.2623
0.62 1.34 ± 0.65 0.2034 1.43 ± 0.82 1.30 ± 0.61 0.4413
0.40 1.23 ± 0.35 0.6162 1.34 ± 0.42 1.22 ± 0.36 0.0526
0.14 0.52 ± 0.16 0.0868 0.51 ± 0.18 0.50 ± 0.14 0.7061
0.51 1.12 ± −0.47 0.6943 1.17 ± 0.50 1.13 ± 0.48 0.6330
5.01 29.91 ± 13.51 0.4044 30.39 ± 5.71 29.29 ± 12.48 0.0269
13.12 95.19 ± 13.34 0.1459 98.64 ± 17.13 93.72 ± 12.41 0.0268
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exclude the possibility that other SNPs or particular hap-
lotypes may have a significant impact on genetic suscep-
tibility to metabolic syndrome. The target of our future
studies is investing the association between high number
of SNPs per gene and genetic susceptibility to metabolic
syndrome, in large cohorts from Moroccan population.
In conclusion, we found that the APOA5 (−1131 T > C
and c.56C > G) variants and haplotypes (CCGT and
CGGT) were significantly associated with susceptibility
to MS in Moroccan patients. This finding suggests that
APOA5 polymorphisms and haplotypes could be used as
predictive indicators for MS in Moroccan population. In
addition, prompt diagnosis and treatment of individuals
with multiple risk factors, and will contribute substan-
tially to prevention by adopting a healthy lifestyle and
reducing future complications.
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